Clinical trial · Observational
Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment
The Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Lenvatinib and Anti-PD-1 Treatment
NCT05443230CI-TRIAL-00069532unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gait speed; ct scan; grip strength and chair stand test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- patients with sarcopenia
- interventionNames
- Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
- label
- patients without sarcopenia
- interventionNames
- Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
Primary outcomes (2)
- measure
- Short-term results
- timeFrame
- 3 months
- description
- Post-treatment complications
- measure
- Long-term results
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Patients with clinical diagnosis of liver cancer * No cancer other than liver cancer has been diagnosed * Age ≥18 years Exclusion Criteria: * Patients who could not complete the standard tests and questionnaires * Patients received other therapies * Patients who had other causes of muscle weakness (injury, fracture, stroke, etc.) * Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3)
References
Publications (3)
- BACKGROUNDHanna L, Nguo K, Furness K, Porter J, Huggins CE. Association between skeletal muscle mass and quality of life in adults with cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):839-857. doi: 10.1002/jcsm.12928. Epub 2022 Feb 13. PMID 35156342
- BACKGROUNDArulananda S, Segelov E. Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers-ready for prime time? Ann Oncol. 2022 Jul;33(7):669-671. doi: 10.1016/j.annonc.2022.04.008. Epub 2022 Apr 14. No abstract available. PMID 35430371
- BACKGROUNDVoron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, Salloum C, Luciani A, Azoulay D. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg. 2015 Jun;261(6):1173-83. doi: 10.1097/SLA.0000000000000743. PMID 24950264